REGN240927P1127500
- 80.00
- +43.50+119.18%
Regeneron Pharmaceuticals Newsroom
Regeneron Pharma Is Maintained at Outperform by RBC Capital
Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Maintains $1200 Price Target
Evercore Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,250
Regeneron Downgraded at Leerink After Amgen's Court Win; Truist Defends
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $1,200 to $1,300
4D Molecular Therapeutics Downgraded at Cantor Following Wet AMD Asset Data
Regeneron Pharmaceuticals Analyst Ratings
Wells Fargo Reiterates Overweight on Regeneron Pharmaceuticals, Maintains $1200 Price Target
Regeneron Pharma Price Target Maintained With a $1282.00/Share by RBC Capital
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,282
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,300
BofA Securities Initiates Regeneron Pharmaceuticals(REGN.US) With Sell Rating, Announces Target Price $805
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
Regeneron Pharmaceuticals Analyst Ratings
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,300
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,183
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
Regeneron Pharma Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,282